Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Litigation Soars In 2014-2015; Patent Office Petitions Also Jump

This article was originally published in The Pink Sheet Daily

Executive Summary

Purdue's OxyContin and Amarin's Vascepa lead the list of targets as an increasing number of generic firms take up litigation.

You may also be interested in...



ANDA Case Filings Drop 32%, But Still High Compared To Last Decade

Lex Machina reports that 316 ANDA cases were filed in 2016 compared to 468 in 2015; number of inter partes review petitions filed on Orange Book patents has declined since 2015.

Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes

Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.

Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages

Teva and Sun are to pay $2.15 billion for their at-risk launch of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel